White Paper | December 16, 2011

9 Questions To Ask Before You Develop A Fixed-Dosage Combination

Source: CoreRX, Inc.
LC - associated files  - pharm4
By Todd Daviau, Ph.D., CoreRX Inc.

In today's competitive pharmaceutical environment, building and maintaining market share is paramount. With dwindling pipelines, limited resources, and expiring patents, now, more than ever, combination products are being considered in drug development portfolios. However, regulatory hurdles, physician acceptance, and market strategy, are just a few considerations that one should address. This brief overview will cover specifics regarding fixed dosage combinations (FDCs), and will hopefully give companies thinking about combination products a better understanding to the challenges ahead.

Patients have already seen the benefit of combination products in areas such as oncology, cardiology, neurological, metabolic disorders, respiratory, HIV, as well as several other areas. Whether you are considering a solid, liquid, or a topical, marketing decision makers need to be well-informed in areas such as the current market, the regulatory environment, and most importantly in the scientific and formulation development challenges.

For full access to this content, please Register or Sign In.

Access Content 9 Questions To Ask Before You Develop A Fixed-Dosage Combination